Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Assets (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Assets for 5 consecutive years, with $763.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 31.54% year-over-year to $763.6 million, compared with a TTM value of $763.6 million through Dec 2025, up 31.54%, and an annual FY2025 reading of $763.6 million, up 31.54% over the prior year.
  • Assets was $763.6 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $712.3 million in the prior quarter.
  • Across five years, Assets topped out at $763.6 million in Q4 2025 and bottomed at $210.6 million in Q2 2022.
  • Average Assets over 5 years is $465.4 million, with a median of $483.7 million recorded in 2023.
  • The sharpest move saw Assets decreased 25.77% in 2022, then surged 130.0% in 2023.
  • Year by year, Assets stood at $232.8 million in 2021, then skyrocketed by 97.45% to $459.7 million in 2022, then rose by 14.5% to $526.3 million in 2023, then grew by 10.3% to $580.6 million in 2024, then skyrocketed by 31.54% to $763.6 million in 2025.
  • Business Quant data shows Assets for KNSA at $763.6 million in Q4 2025, $712.3 million in Q3 2025, and $661.2 million in Q2 2025.